JP5016731B2 - 生弱毒化呼吸器合胞体ウイルス - Google Patents

生弱毒化呼吸器合胞体ウイルス Download PDF

Info

Publication number
JP5016731B2
JP5016731B2 JP2011534864A JP2011534864A JP5016731B2 JP 5016731 B2 JP5016731 B2 JP 5016731B2 JP 2011534864 A JP2011534864 A JP 2011534864A JP 2011534864 A JP2011534864 A JP 2011534864A JP 5016731 B2 JP5016731 B2 JP 5016731B2
Authority
JP
Japan
Prior art keywords
rsv
seq
virus
nucleotide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011534864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507302A5 (cg-RX-API-DMAC7.html
JP2012507302A (ja
Inventor
ヤゴデイツヒ，メアリー・ケイ
シトロン，マイケル・ピー
デイステフアノ，ダニエル・ジエイ
クラー，デイビツド・エル
リアン，シアオピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2012507302A publication Critical patent/JP2012507302A/ja
Publication of JP2012507302A5 publication Critical patent/JP2012507302A5/ja
Application granted granted Critical
Publication of JP5016731B2 publication Critical patent/JP5016731B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2011534864A 2008-11-05 2009-11-03 生弱毒化呼吸器合胞体ウイルス Expired - Fee Related JP5016731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05
US61/198,327 2008-11-05
PCT/US2009/063024 WO2010053883A1 (en) 2008-11-05 2009-11-03 Live, attentuated respiratory syncytial virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011171459A Division JP5743794B2 (ja) 2008-11-05 2011-08-05 生弱毒化呼吸器合胞体ウイルス

Publications (3)

Publication Number Publication Date
JP2012507302A JP2012507302A (ja) 2012-03-29
JP2012507302A5 JP2012507302A5 (cg-RX-API-DMAC7.html) 2012-05-17
JP5016731B2 true JP5016731B2 (ja) 2012-09-05

Family

ID=41527812

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011534864A Expired - Fee Related JP5016731B2 (ja) 2008-11-05 2009-11-03 生弱毒化呼吸器合胞体ウイルス
JP2011171459A Expired - Fee Related JP5743794B2 (ja) 2008-11-05 2011-08-05 生弱毒化呼吸器合胞体ウイルス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011171459A Expired - Fee Related JP5743794B2 (ja) 2008-11-05 2011-08-05 生弱毒化呼吸器合胞体ウイルス

Country Status (19)

Country Link
US (1) US9011876B2 (cg-RX-API-DMAC7.html)
EP (1) EP2346990B1 (cg-RX-API-DMAC7.html)
JP (2) JP5016731B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110063863A (cg-RX-API-DMAC7.html)
CN (1) CN102272295A (cg-RX-API-DMAC7.html)
AU (1) AU2009311287C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921424A2 (cg-RX-API-DMAC7.html)
CA (1) CA2742086A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011000999A1 (cg-RX-API-DMAC7.html)
CO (1) CO6362047A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011033A (cg-RX-API-DMAC7.html)
IL (1) IL212437A0 (cg-RX-API-DMAC7.html)
MA (1) MA32878B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011004719A (cg-RX-API-DMAC7.html)
PE (1) PE20110394A1 (cg-RX-API-DMAC7.html)
RU (1) RU2011122615A (cg-RX-API-DMAC7.html)
TN (1) TN2011000182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010053883A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103259B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0921424A2 (pt) * 2008-11-05 2016-01-05 Merck Sharp & Dohme vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
WO2013026054A2 (en) * 2011-08-18 2013-02-21 Axella Solutions, Llc Production of infectious rna viruses in yeast
US9463236B2 (en) 2011-08-29 2016-10-11 Tokushima University RSV mucosal vaccine
CA2900713A1 (en) 2013-02-08 2014-08-14 Steffen Mueller Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
CN105189756B (zh) * 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
EP3057978B1 (en) 2013-10-16 2022-09-14 Merck Sharp & Dohme LLC Method of microwave vacuum drying spherical-shaped pellets of biological materials
WO2015057548A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
US10947512B2 (en) * 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods
SG11201803581VA (en) 2015-10-29 2018-05-30 Univ Emory Chimeric RSV, Immunogenic Compositions, and Methods of Use
AU2017332789B2 (en) 2016-09-23 2021-05-27 Codagenix, Inc. Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
EP3681523A4 (en) * 2017-09-15 2021-12-29 The Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
AU2024380679A1 (en) * 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0917592A4 (en) * 1996-04-04 2002-04-24 Univ Michigan REDUCED RSV
IL138681A0 (en) 1998-03-26 2001-10-31 American Cyanamid Co Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
CN101260386A (zh) 1999-07-09 2008-09-10 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
JP2007531491A (ja) 2002-09-27 2007-11-08 メディミューン・ヴァクシンズ・インコーポレーテッド 呼吸器合胞体ウイルスにおける機能的突然変異
WO2004087062A2 (en) * 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
KR20090114431A (ko) * 2007-02-07 2009-11-03 디나벡크 가부시키가이샤 약독화 마이너스 가닥 ｒｎａ 바이러스
BRPI0921424A2 (pt) * 2008-11-05 2016-01-05 Merck Sharp & Dohme vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.

Also Published As

Publication number Publication date
IL212437A0 (en) 2011-06-30
EP2346990A1 (en) 2011-07-27
CN102272295A (zh) 2011-12-07
CA2742086A1 (en) 2010-05-14
ECSP11011033A (es) 2011-12-30
AU2009311287C1 (en) 2015-02-19
JP5743794B2 (ja) 2015-07-01
KR20110063863A (ko) 2011-06-14
JP2011250798A (ja) 2011-12-15
TN2011000182A1 (en) 2012-12-17
AU2009311287A1 (en) 2010-05-14
BRPI0921424A2 (pt) 2016-01-05
CO6362047A2 (es) 2012-01-20
ZA201103259B (en) 2012-01-25
RU2011122615A (ru) 2012-12-20
MA32878B1 (fr) 2011-12-01
AU2009311287B2 (en) 2013-02-07
CL2011000999A1 (es) 2012-07-20
PE20110394A1 (es) 2011-06-22
US9011876B2 (en) 2015-04-21
WO2010053883A1 (en) 2010-05-14
JP2012507302A (ja) 2012-03-29
US20110212130A1 (en) 2011-09-01
EP2346990B1 (en) 2016-01-06
MX2011004719A (es) 2011-05-31

Similar Documents

Publication Publication Date Title
JP5743794B2 (ja) 生弱毒化呼吸器合胞体ウイルス
JP2012507302A5 (cg-RX-API-DMAC7.html)
JP2011250798A5 (cg-RX-API-DMAC7.html)
AU2021218112B2 (en) Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
US10980872B2 (en) Genetically stable live attenuated respiratory syncytial virus vaccine and its production
US10329584B2 (en) Modified Sendai virus vaccine and imaging vector
JP7079197B2 (ja) さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株
HK40057493A (en) Genetically stable live attenuated respiratory syncytial virus vaccine and its production

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120124

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120515

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120608

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150615

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150615

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees